A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
The purpose of this study is to evaluate the safety and efficacy of 34 mg pimavanserin compared to placebo in patients with Parkinson\'s disease psychosis (PDP).
Epistemonikos ID: b427443acc71a39471bbc0bab41da1b44e9f1137
First added on: May 15, 2024